OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
March 18, 2022
Sanofi and Seagen have entered an agreement to investigate three cancer targets.
March 17, 2022
Catalent has announced the completion of a $30 million project at its facility in Limoges, France focused on biopharmaceutical development and drug product manufacturing.
March 16, 2022
NIH has launched one of the first Phase 1 clinical trials to examine mRNA technology for HIV.
March 11, 2022
C4 Therapeutics has been granted orphan drug designation by FDA for CFT8634 for the treatment of soft tissue sarcoma.
SCG Cell Therapy has signed a collaboration agreement with A*STAR’s BTI to advance the development of antibodies for infectious diseases and cancer treatments.
March 10, 2022
Novo Nordisk will expand its existing research collaboration in novel delivery technologies with MIT and Brigham and Women’s Hospital.
Evonik has launched new EUDRATEC technology to improve solubility and performance of oral small molecules.
March 08, 2022
Oculis has gained exclusive global rights to neuroprotective drug candidate for glaucoma through a licensing agreement with Accure Therapeutics.
March 07, 2022
Researchers at McGill University have made advancements with a novel method for growing synthetic bone tissue.
March 04, 2022
FDA’s CDER continues to make rare diseases a priority with drug approvals and programming to speed therapeutic development.